Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
Related Questions
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
Are there any trans-cathter options available in a patient s/p m-TEER with residual severe MR with high surgical risk who has worsening heart failure symptoms?
What would be your approach for the management of asymptomatic, severe AS with a peak velocity of 5 m/s in an otherwise physically active patient in their mid-90s without significant co-morbidities?
How would you approach anticoagulation management and consideration for PFO closure in patients with acute lower extremity DVTs involving the proximal deep veins and findings concerning for PFO on echocardiogram?
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
How do you decide the duration of DAPT following TAVR, especially for patients already on a DOAC?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
In patients with contraindications to TEE and poor windows for TTE, what is the next best test to look for PFO?
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
Is there any role for routine CT TAVR a few months after TAVR to look for HALT?
